Form 4: SOPHiA GENETICS Officer Sells Shares Under 10b5-1 Plan

SOPHiA GENETICS SA reports a Form 4 filing detailing a Chief People Officer's sale of ordinary shares to cover tax obligations, executed under a pre-arranged trading plan.

Summary

• Manuela Valente, Chief People Officer of SOPHiA GENETICS SA, sold 4,241 ordinary shares on July 6, 2026.
• The sale was conducted under a Rule 10b5-1(c) trading plan to satisfy tax withholding obligations related to the vesting of restricted stock units.
• The shares were sold at a weighted average price of $5.053, with individual sales ranging from $4.95 to $5.34.
• Following the transaction, Valente beneficially owns 210,450 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sale is a standard transaction for tax purposes under a pre-arranged plan, rather than an indicator of management's view on the company's future prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating adherence to pre-defined trading strategies and potentially mitigating insider trading concerns.
• The sale was specifically to cover tax withholding obligations, a common and often necessary event for executives upon vesting of equity awards.

Negatives

• A sale of company stock by a key executive, even if for tax purposes, can sometimes be perceived negatively by the market.
• The sale represents a reduction in the executive's direct beneficial ownership of the company's shares.

Risks

• The filing does not explicitly mention any new or emerging risks.
• The primary risk associated with this type of filing is the market's interpretation of insider selling, regardless of the stated reason.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports a past transaction.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for public companies and often reflect standard executive compensation practices, such as selling shares to cover tax liabilities. The use of a Rule 10b5-1 plan is a common mechanism for executives to manage their stock holdings in a compliant manner.

Stakeholder Impact

• Shareholders: May observe a slight decrease in insider ownership, though the transaction is structured to minimize negative perception.
• Employees: The transaction is related to executive compensation and tax obligations, with no direct impact on general employee equity or benefits.
• Creditors: No direct impact.
• Suppliers: No direct impact.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• The company may receive written requests for detailed sales information from stakeholders or the SEC.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding, Beneficial Ownership